A roadmap for driving CAR T cells toward the oncogenic immunopeptidome

Cancer Cell. 2022 Jan 10;40(1):20-22. doi: 10.1016/j.ccell.2021.12.011.


A critical barrier to CAR T cell therapy is the paucity of target antigens that are broadly and stably expressed exclusively in tumors. In their comprehensive multi-omics and pre-clinical study, Yarmarkovich et al. provide proof of principle for the development and efficacy of peptide centric (PC)-CARs targeting the oncogenic immunopeptidome of neuroblastoma.

Publication types

  • Comment

MeSH terms

  • Carcinogenesis
  • Humans
  • Immunotherapy, Adoptive*
  • Neuroblastoma*
  • T-Lymphocytes